About Pharmaceutical Contract Manufacturing
Contract manufacturing involves outsourcing manufacturing products to organizations, which helps the organizations offer the same services at a relatively lower cost. Typically, in the pharmaceutical and biotechnology sectors, the sourcing companies seek contract manufacturing services to restructure their resource deployment toward high skill areas such as R&D and marketing. Contract manufacturing has potential growth opportunities in emerging countries such as India and China.
Technavio’s analysts forecast the global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calculate the market size, the report considers the revenue generated from various pharmaceutical drug manufacturing outsourcing activities.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Pharmaceutical Contract Manufacturing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Catalent
• Lonza
• Pfizer CentreOne
Other prominent vendors
• Abbott
• Aenova
• Amgen
• Apotex
• Aspen
• AstraZeneca
• Aurobindo Pharma
• Baxter
• BERLIN-CHEMIE
• Biocon
• Biogen
• Boehringer Ingelheim
• Celltrion
• Cipla
• Coherus Biosciences
• Daiichi Sankyo
• Dr. Reddy's Laboratories
• Eli Lilly
• Emcure Pharmaceuticals
• Eurofarma Laboratories
• Fareva
• Gedeon Richter
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Hospira
• Impax Laboratories
• Intas Pharmaceuticals
• Janssen Pharmaceuticals
• Lupin
• Merck
• Mitsubishi Tanabe Pharma
• Momenta Pharmaceuticals
• Natco Pharma
• Nexus Pharmaceuticals
• Novo Nordisk
• Orchid Chemicals & Pharmaceuticals
• Par Pharmaceutical
• Parenteral Drugs India
• Patheon
• Piramal
• Roche Holding
• Sanofi
• Synthon
• Teva Pharmaceuticals
• Valeant Pharmaceuticals
• Zentiva
• Zhejiang Huahai Pharmaceutical
• Zydus Cadila
Market driver
• High number of US FDA-approved manufacturing facilities in emerging countries.
• For a full, detailed list, view our report
Market challenge
• Capacity utilization issues and lack of information integration.
• For a full, detailed list, view our report
Market trend
• Huge demand for next-generation biologics.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Pharmaceutical manufacturing outsourcing
• Increased regulatory guidelines coupled with healthcare cost containment efforts
• Rapid innovation and reduced product development lifecycle
• High capital investment
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by type of contract manufacturing
• Global API/bulk drug contract manufacturing market
• Global FDF market
PART 08: Geographical segmentation
• Global pharmaceutical contract manufacturing market by geography
• Pharmaceutical contract manufacturing market in Americas
• Pharmaceutical contract manufacturing market in APAC
• Pharmaceutical contract manufacturing market in EMEA
PART 09: Key leading countries
PART 10: Market drivers
• Increased focus on core competence
• High number of US FDA-approved manufacturing facilities in emerging countries
• Shorter time-to-market
PART 11: Impact of drivers
PART 12: Market challenges
• Capacity utilization issues and lack of information integration
• Growing global competition
• Lack of manufacturing standardization
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Consolidation through vertical integration, alliances, and acquisitions
• Huge demand for next-generation biologics
• Value-added services
PART 15: Vendor landscape
• Competitive scenario
PART 16: Key vendor analysis
• Catalent
• Lonza
• Pfizer CentreOne
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
?
List of Exhibits
Exhibit 01: Service offerings
Exhibit 02: Overview of global pharmaceutical contract manufacturing market
Exhibit 03: Global pharmaceutical contract manufacturing market: Present and future scenario
Exhibit 04: Process of drug development
Exhibit 05: Value chain of pharmaceutical industry
Exhibit 06: Contract manufacturing market: Benefit analysis
Exhibit 07: Factors affecting pharmaceutical manufacturing outsourcing
Exhibit 08: Key factors and its impact on selection of CMOs
Exhibit 09: Global pharmaceutical contract manufacturing market: Market overview
Exhibit 10: CMO market growth
Exhibit 11: Overview of outsourced new drug abbreviations (NDAs) in CMO industry
Exhibit 12: Cost comparison of drug development in the US and India
Exhibit 13: Global pharmaceutical contract manufacturing market 2015-2020 ($ billions)
Exhibit 14: Average number of services outsourced by company type 2013-2015
Exhibit 15: Preference for choosing pharmaceutical outsourcing partners
Exhibit 16: Factors affecting the global pharmaceutical contract manufacturing market
Exhibit 17: Opportunities analysis: Global pharmaceutical contract manufacturing market
Exhibit 18: Growth of global pharmaceutical contract manufacturing market 2016-2020
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation based on type of contract manufacturing
Exhibit 21: Segment outlook
Exhibit 22: Market overview of global API/bulk drug manufacturing market
Exhibit 23: Global API/bulk drug contract manufacturing market 2015-2020 ($ billions)
Exhibit 24: Global API/bulk drug contract manufacturing market
Exhibit 25: Overview of API outsourcing manufacturing market
Exhibit 26: Market share of global FDF market 2015
Exhibit 27: Types of dosage forms
Exhibit 28: Lifecycle analysis of dosage formulations
Exhibit 29: Global FDF market 2015-2020 ($ billions)
Exhibit 30: Market share of global pharmaceutical contract manufacturing market 2015
Exhibit 31: Global pharmaceutical contract manufacturing market: Geography outlook 2015-2020
Exhibit 32: Global pharmaceutical contract manufacturing market: Current and future impact
Exhibit 33: Pharmaceutical contract manufacturing market in Americas 2015-2020 ($ billions)
Exhibit 34: Pharmaceutical contract manufacturing market in APAC 2015-2020 ($ billions)
Exhibit 35: Pharmaceutical contract manufacturing market in EMEA 2015-2020 ($ billions)
Exhibit 36: Key leading countries
Exhibit 37: Impact of drivers and challenges on global pharmaceutical contract manufacturing market
Exhibit 38: Competitive advantage
Exhibit 39: Examples of global pharmaceutical companies sourcing from CMOs
Exhibit 40: Impact of drivers
Exhibit 41: Capacity constraints by stage production 2015
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Impact of trends on global pharmaceutical contract manufacturing market
Exhibit 44: Major M&A in global pharmaceutical contract manufacturing market
Exhibit 45: Key vendors: Geographical presence 2015
Exhibit 46: Catalent: Profile
Exhibit 47: Catalent: Metrics analysis
Exhibit 48: Catalent: Growth strategy matrix
Exhibit 49: Catalent: Opportunity assessment
Exhibit 50: Lonza: Profile
Exhibit 51: Lonza: Metrics analysis
Exhibit 52: Lonza: Growth strategy matrix
Exhibit 53: Lonza: Opportunity assessment
Exhibit 54: Pfizer CentreOne: Profile
Exhibit 55: Pfizer CentreOne profile: Metrics analysis
Exhibit 56: Pfizer CentreOne: Growth strategy matrix
Exhibit 57: Pfizer CentreOne: Growth opportunity assessment
